Genomics in Cancer Care Market Report 2025

The genomics in cancer care market size has grown rapidly in recent years. It will grow from $17.6 billion in 2024 to $20.73 billion in 2025 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to early research and development, development of companion diagnostics, ethical and legal frameworks, data standardization and interpretation, initial market penetration.

The genomics in cancer care market size is expected to see rapid growth in the next few years. It will grow to $38.57 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to increasing prevalence of cancer, advancements in data analytics, market expansion in emerging economies, genomic data privacy and security, improving healthcare infrastructure. Major trends in the forecast period include technological advancements, personalized medicine, reduced costs of genomic sequencing, regulatory support and guidelines, patient awareness and demand.

The increasing demand for cancer diagnostics is projected to boost the role of genomics in the cancer care market. Cancer diagnostics involves identifying the specific type, location, extent, and stage of tumors through various tests and procedures that confirm the presence of the disease. Genomics in cancer care aids in formulating appropriate treatment plans for patients by analyzing their genetic profiles. For instance, a report from Cancer Research UK, a UK-based cancer research organization, indicated in July 2024 that the average annual number of new cancer cases in the UK is anticipated to rise from approximately 420,000 cases between 2023 and 2025 to around 506,000 cases by 2038-2040. Therefore, the growing demand for cancer diagnostics is expected to drive the advancement of genomics in the cancer care market.

The genomics in cancer care market is experiencing growth, propelled by an increase in funding and investments for genomics research in cancer. Significant financial resources are being directed towards companies and initiatives advancing genomics technologies in cancer care. Investors are particularly interested in supporting innovative technologies, ranging from next-generation sequencing platforms to liquid biopsy assays, which provide comprehensive genomic profiling and non-invasive monitoring of cancer progression. Notably, the UK government's substantial investment of around £175 million to boost genomics research underscores the increasing financial support for cutting-edge genomic healthcare solutions. This influx of funding and investments is a key factor driving the growth of the genomics in cancer care market.

Leading companies in the genomics in cancer care market are prioritizing the introduction of robotic genomic testing facilities to improve the accuracy and efficiency of genetic testing, decrease turnaround times, and enhance patient outcomes through personalized treatment strategies tailored to individual genetic profiles. Robotic genomic testing facilities are advanced laboratory environments equipped with automated systems and robotic technologies designed to conduct various genomic analyses. For example, utilizing Automata’s LINQ platform, the lab features six robotic arms that automate the preparation of samples from different biological materials, such as saliva, blood, bone marrow, and tissue biopsies. In September 2024, The Royal Marsden NHS Foundation Trust, a UK-based cancer hospital, launched a robotic genomic testing facility aimed at improving cancer diagnosis and treatment. This facility will double the genomic testing capacity of the Royal Marsden, enabling a higher volume of tests to be processed without sacrificing accuracy.

Major companies operating in the genomics in cancer care market are engaging in strategic partnerships to strengthen their positions. These partnerships involve structured affiliations between commercial enterprises, often established through business agreements or contracts. The collaboration between C2i Genomics and Karkinos Healthcare exemplifies this trend, where innovative cancer detection technology is brought together with the goal of driving research and development (R&D), establishing future pharma partnerships, and facilitating clinical use in India. Such strategic partnerships contribute to the expansion and global scalability of genomics in cancer care technologies, fostering growth and development in the market.

In December 2023, Pfizer Inc., a US-based company, completed the acquisition of Seagen Inc. for $43 billion. This acquisition is intended to enhance Pfizer's portfolio by integrating Seagen's expertise in delivering cancer care through innovative genomic approaches. Seagen Inc. specializes in providing cancer treatment using advanced genomic strategies.

Major companies operating in the genomics in cancer care market are Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Danaher Corporation, Pacific Biosciences of California Inc., Roche Holding AG, Quest Diagnostics Incorporated, DiaSorin S.p.A., BGI Group, Myriad Genetics Inc., NeoGenomics Laboratories, Foundation Medicine Inc., Intermountain Healthcare, Laboratory Corporation of America Holdings, Flatiron Health Inc., Personal Genome Diagnostics Inc., Natera Inc., GRAIL Inc., Freenome Holdings Inc., Caris Life Sciences Inc., Tempus Labs Inc., OncoDNA S.A., Biocept Inc., GenomOncology Corp., OncoCyte Corporation, PathAI Inc., Enzyme Corporation, Karius Inc., N-of-One Inc., Oncora Medical Inc., Paradigm Diagnostics Inc., PierianDx Inc., Predicine Inc., Resolution Bioscience Inc., Strata Oncology Inc.

North America was the largest region in the genomics in cancer care market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomics in cancer care market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomics in cancer care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genomics in cancer care involves the comprehensive examination of all variations in DNA sequence and gene expression between tumor cells and healthy host cells. This approach aims to identify patients' genetic backgrounds for more effective cancer treatment. Genomics in cancer care is utilized to detect cancer-causing mutations, improve tumor-specific diagnostic techniques and treatment plans, facilitate precision medicine research and drug development, and enable the creation of targeted therapies to offer personalized treatment to patients with various types of cancers.

The main product types in genomics for cancer care include instruments, consumables, and services. Instruments are devices or equipment used for the detection of tumors in cancer genomics, providing accurate diagnostics. Various technologies, such as PCR, microarrays, genome sequencing, and others, are employed in these instruments. The applications of genomics in cancer care span diagnostics, personalized medicine, drug discovery and development, and research. These applications are utilized by hospitals, government institutes, and research facilities to enhance cancer diagnosis and treatment strategies.

The genomics in cancer care market research report is one of a series of new reports that provides genomics in cancer care market statistics, including genomics in cancer care industry global market size, regional shares, competitors with a genomics in cancer care market share, detailed genomics in cancer care market segments, market trends and opportunities, and any further data you may need to thrive in the genomics in cancer care industry. This genomics in cancer care market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genomics in the cancer care market consists of revenues earned by entities by providing sequencing to identify DNA and RNA alterations, and defining molecular subtypes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.